Economic burden of multiple sclerosis: a cross-sectional study in Iran
Abstract Background Multiple Sclerosis (MS) is a chronic debilitating disease that imposes a heavy socioeconomic burden on societies. This study aimed to determine the economic burden of MS on patients using the first (CinnoVex and ReciGen) and second (Fingolimod and Natalizumab) drug therapy lines....
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-01-01
|
| Series: | Health Economics Review |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13561-021-00350-y |
| _version_ | 1798034683515109376 |
|---|---|
| author | Mehdi Rezaee Khosro Keshavarz Sadegh Izadi Abdosaleh Jafari Ramin Ravangard |
| author_facet | Mehdi Rezaee Khosro Keshavarz Sadegh Izadi Abdosaleh Jafari Ramin Ravangard |
| author_sort | Mehdi Rezaee |
| collection | DOAJ |
| description | Abstract Background Multiple Sclerosis (MS) is a chronic debilitating disease that imposes a heavy socioeconomic burden on societies. This study aimed to determine the economic burden of MS on patients using the first (CinnoVex and ReciGen) and second (Fingolimod and Natalizumab) drug therapy lines. Methods This cost of illness study was an economic evaluation carried out as cross-sectional research in 2019 in southern Iran. A total of 259 patients were enrolled in two lines of drug therapy (178 patients in the first line and 81 ones in the second). The prevalence-based approach and the bottom-up approach were used to collect cost information and to calculate the costs from the societal perspective, respectively. The human capital approach was applied to calculate indirect costs. To collect the required data a researcher-made data collection form was utilized. The data were obtained using the information available in the patients’ medical records and insurance invoices as well as their self-reports or that of their companions. Results The results showed that the annual costs of MS in the first and second lines of drug therapy per patient were $ 1919 and $ 4082 purchasing power parity (PPP), respectively, and in total, $ 2721 PPP in 2019. The highest mean costs in both lines were those of direct medical costs, of which purchasing the main medicines in both lines accounted for the highest. Conclusion Considering the findings of this study and in order to reduce the burden of the disease, the following suggestions are presented: providing necessary facilities for the production of MS drugs in the country; proper and equitable distribution of neurologists; expanding the provision of home care services; and using the technologies related to the Internet, including WhatsApp, to follow up the MS patients’ treatment. |
| first_indexed | 2024-04-11T20:47:38Z |
| format | Article |
| id | doaj.art-dee511f5eff24d51a697011cd890dbf1 |
| institution | Directory Open Access Journal |
| issn | 2191-1991 |
| language | English |
| last_indexed | 2024-04-11T20:47:38Z |
| publishDate | 2022-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Health Economics Review |
| spelling | doaj.art-dee511f5eff24d51a697011cd890dbf12022-12-22T04:03:58ZengBMCHealth Economics Review2191-19912022-01-0112111010.1186/s13561-021-00350-yEconomic burden of multiple sclerosis: a cross-sectional study in IranMehdi Rezaee0Khosro Keshavarz1Sadegh Izadi2Abdosaleh Jafari3Ramin Ravangard4Student Research Committee, School of Management and Medical Information Sciences, Shiraz University of Medical SciencesDepartment of Health Services Management, School of Management and Medical Information Sciences, Shiraz University of Medical SciencesClinical Neurology Research Center, Medical School, Shiraz University of Medical SciencesDepartment of Health Services Management, School of Management and Medical Information Sciences, Shiraz University of Medical SciencesDepartment of Health Services Management, School of Management and Medical Information Sciences, Shiraz University of Medical SciencesAbstract Background Multiple Sclerosis (MS) is a chronic debilitating disease that imposes a heavy socioeconomic burden on societies. This study aimed to determine the economic burden of MS on patients using the first (CinnoVex and ReciGen) and second (Fingolimod and Natalizumab) drug therapy lines. Methods This cost of illness study was an economic evaluation carried out as cross-sectional research in 2019 in southern Iran. A total of 259 patients were enrolled in two lines of drug therapy (178 patients in the first line and 81 ones in the second). The prevalence-based approach and the bottom-up approach were used to collect cost information and to calculate the costs from the societal perspective, respectively. The human capital approach was applied to calculate indirect costs. To collect the required data a researcher-made data collection form was utilized. The data were obtained using the information available in the patients’ medical records and insurance invoices as well as their self-reports or that of their companions. Results The results showed that the annual costs of MS in the first and second lines of drug therapy per patient were $ 1919 and $ 4082 purchasing power parity (PPP), respectively, and in total, $ 2721 PPP in 2019. The highest mean costs in both lines were those of direct medical costs, of which purchasing the main medicines in both lines accounted for the highest. Conclusion Considering the findings of this study and in order to reduce the burden of the disease, the following suggestions are presented: providing necessary facilities for the production of MS drugs in the country; proper and equitable distribution of neurologists; expanding the provision of home care services; and using the technologies related to the Internet, including WhatsApp, to follow up the MS patients’ treatment.https://doi.org/10.1186/s13561-021-00350-yEconomic burdenMultiple sclerosis (MS)Direct medical costsDirect non-medical costsIndirect costs |
| spellingShingle | Mehdi Rezaee Khosro Keshavarz Sadegh Izadi Abdosaleh Jafari Ramin Ravangard Economic burden of multiple sclerosis: a cross-sectional study in Iran Health Economics Review Economic burden Multiple sclerosis (MS) Direct medical costs Direct non-medical costs Indirect costs |
| title | Economic burden of multiple sclerosis: a cross-sectional study in Iran |
| title_full | Economic burden of multiple sclerosis: a cross-sectional study in Iran |
| title_fullStr | Economic burden of multiple sclerosis: a cross-sectional study in Iran |
| title_full_unstemmed | Economic burden of multiple sclerosis: a cross-sectional study in Iran |
| title_short | Economic burden of multiple sclerosis: a cross-sectional study in Iran |
| title_sort | economic burden of multiple sclerosis a cross sectional study in iran |
| topic | Economic burden Multiple sclerosis (MS) Direct medical costs Direct non-medical costs Indirect costs |
| url | https://doi.org/10.1186/s13561-021-00350-y |
| work_keys_str_mv | AT mehdirezaee economicburdenofmultiplesclerosisacrosssectionalstudyiniran AT khosrokeshavarz economicburdenofmultiplesclerosisacrosssectionalstudyiniran AT sadeghizadi economicburdenofmultiplesclerosisacrosssectionalstudyiniran AT abdosalehjafari economicburdenofmultiplesclerosisacrosssectionalstudyiniran AT raminravangard economicburdenofmultiplesclerosisacrosssectionalstudyiniran |